The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy
- 21 January 2016
- journal article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 9 (3) , 223-225
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Dysfunctional nitric oxide signalling increases risk of myocardial infarctionNature, 2013
- Blockade of the purinergic P2Y 12 receptor greatly increases the platelet inhibitory actions of nitric oxideProceedings of the National Academy of Sciences, 2013
- Targeting Phosphodiesterases in Anti-platelet Therapy2012
- Nitric oxide‐sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibitionJournal of Thrombosis and Haemostasis, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery DiseaseThe American Journal of Cardiology, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclinJournal of Thrombosis and Haemostasis, 2007
- Spatial and temporal dynamics of the endotheliumJournal of Thrombosis and Haemostasis, 2005
- Taming platelets with cyclic nucleotides11Abbreviations: ABP, actin binding protein; AC, adenylyl cyclase; cAMP, cyclic AMP; cAMP-PK, cAMP-dependent protein kinase; cGMP, cyclic GMP; cGMP-PK, cGMP-dependent protein kinase; DAG, 1,2-diacylglycerol; EDRF, endothelium-derived relaxing factor; GC, guanylyl cyclase; GP, glycoprotein; Hsp27, heat shock protein 27; IP3, inositol 1,4,5- trisphosphate; IRAG, IP3 receptor-associated cGMP-PK substrate; MAPK, mitogen-activated protein kinase; MAPKAPK-2, MAPK-activated protein kinase-2; MARCKS, myristoylated alanine-rich C kinase substrate; MLC, myosin light chain; MLCK, myosin light chain kinase; PDE, phosphodiesterase; PG-E1, prostaglandin E1; PG-I2, prostacyclin; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; TxA2, thromboxane A2, and VASP, vasodilator-stimulated phosphoprotein.Biochemical Pharmacology, 2001